Ascendis Pharma A/S (NASDAQ:ASND) Given New $168.00 Price Target at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective boosted by stock analysts at JPMorgan Chase & Co. from $167.00 to $168.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 16.17% from the stock’s previous close.

Several other research firms have also commented on ASND. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. TD Cowen reduced their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, Oppenheimer lowered their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $191.64.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock traded up $18.47 during midday trading on Thursday, reaching $144.61. 692,784 shares of the company traded hands, compared to its average volume of 462,514. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The firm has a market capitalization of $8.78 billion, a price-to-earnings ratio of -17.97 and a beta of 0.64. The business has a 50 day moving average of $131.98 and a two-hundred day moving average of $132.22.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. As a group, equities analysts forecast that Ascendis Pharma A/S will post -7.12 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in ASND. Signaturefd LLC raised its position in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares in the last quarter. Legato Capital Management LLC raised its holdings in Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 134 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 197 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Finally, GAMMA Investing LLC grew its position in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after buying an additional 214 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.